Ask AI
ProCE Banner Series

Translating Evidence Into Practice: Pharmacist-Led Optimization of Adjuvant CDK4/6 Therapy in High-Risk HR+/HER2- Early Breast Cancer

Join us in person or virtually for this interactive “Myth Busters” symposium designed to help pharmacists translate emerging evidence on adjuvant CDK4/6 inhibitors into confident, real-world decision-making, with case-based discussions focused on patient selection, endpoint interpretation, toxicity management, and long-term adherence in high-risk HR-positive/HER2-negative early breast cancer.

An independent, commercially supported symposium held in conjunction with the HOPA 2026 Annual Conference.

  ACPE
Who Should Attend

This activity is intended for oncology pharmacists and other healthcare professionals involved in the management of patients with high-risk HR-positive/HER2-negative EBC.

All Events

Translating Evidence Into Practice: Pharmacist-Led Optimization of Adjuvant CDK4/6 Therapy in High-Risk HR+/HER2- Early Breast Cancer

Upcoming Events

March

27

2026

11:45 AM - 1:00 PM Central Time (CT)

In-person

Ernest N. Morial Convention Center, 900 Convention Center Blvd., New Orleans, Louisiana 70130

12:00 PM - 1:00 PM Central Time (CT)

Virtual

Topics

Breast cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The activity aims to improve learners’ knowledge, competence, and confidence in translating evolving adjuvant CDK4/6 inhibitor evidence into consistent, high-quality practice in the management of patients with high-risk HR-positive, HER2-negative EBC. 

Target Audience
This activity is intended for oncology pharmacists and other healthcare professionals involved in the management of patients with high-risk HR-positive/HER2-negative EBC.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Interpret key efficacy endpoints, including IDFS and OS, from pivotal adjuvant CDK4/6 inhibitor trials and apply these data to appropriate, guideline-aligned use in high-risk HR+/HER2- EBC
  • Implement evidence-based, pharmacist-led strategies to support patient selection and personalization of adjuvant CDK4/6 inhibitor therapy, incorporating individual risk factors, treatment goals, and regimen duration
  • Proactively identify, monitor, and manage treatment-related toxicities, including appropriate dose modification strategies, to maintain therapeutic intent while supporting adherence and persistence with long-duration oral therapy
  • Apply effective patient and multidisciplinary communication approaches to reinforce adherence, persistence, and shared decision-making throughout the adjuvant CDK4/6 treatment course

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-26-164-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Lilly.

Lilly

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191